ACVRL1 and pulmonary arterial hypertension: Girerd et al. compared 32 patients with an ALK1 mutation to 93 with a BMPR2 mutation and 277 with idiopathic PAH and found that ALK1 patients had earlier presentation and shorter survival compared to the other groups [9].